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INTRODUCTION
Leishmaniasis is a group of parasitic diseases caused
by protozoan parasites of the genus Leishmania, trans-
mitted by the species of phlebotomine sandflies1, with
several disease manifestations ranging from cutaneous to
visceral forms2. It is endemic in >80 countries of the
world3. Cutaneous leishmaniasis (CL) is the most com-
mon disease phenotype in Iran4. It can not only develop
to visceral or mucocutaneous forms, but can also cause
destructive effects on mental health5. Hence, control and
prevention of this parasitic disease is very essential.
Some studies in mice have shown that the stage of
macrophage maturation involves resistance to infections
with intracellular pathogens6–7. Host genetics might play
an important role in microbicidal activity of macrophages
and susceptibility to intracellular bacteria and parasites8–
10. Natural resistance-associated macrophage protein 1
(NRAMP1) gene is a member of the solute carrier family
11 (proton-coupled divalent metal ion transporter), mem-
ber A1 (SLC11A1)9–12. In humans, NRAMP1 gene is located
in the chromosome region 2q35, containing 16 exons13. In
a resting macrophage, the protein encoded by NRAMP1 is
assembled into the membrane of late endosome; while fol-
lowing phagocytosis it is relocated to the membrane of
phagosome14. This protein transfers divalent metal ions
across the phagosomal membrane and might be a critical
factor for resistance to some microbial infections. NRAMP1
influences a variety of antimicrobial responses of a mac-
rophage, including induction of radical oxygen and nitric
oxide intermediates, production and activation of various
pro-inflammatory cytokines (TNF-α and interleukin-1β)
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ABSTRACT
Background & objectives: Association between polymorphisms in the natural resistance associated macrophage
protein 1 (NRAMP1) gene and susceptibility to cutaneous leishmaniasis (CL) has been demonstrated worldwide;
however, the reported results were inconsistent. This study aimed to determine the association of NRAMP1 variants
with susceptibility to CL infection and patients’ response to treatment in Isfahan province of Iran.
Methods: Peripheral blood samples were collected from 150 patients with CL and 136 healthy controls. The CL
patients were treated with intralesional injection of meglumine antimoniate. The polymorphic variants at NRAMP1
(A318V and D543N) were analyzed using PCR-RFLP. The chi-square test and Fisher’s exact test were used to
compare frequencies of alleles and genotypes of polymorphisms between patient and healthy control populations.
Results: There was a statistically significant difference in the D543N (rs17235409) polymorphism between the
CL patients and healthy controls (p=0.008). However, no significant association was detected for A318V
(rs201565523) polymorphism between groups (p=0.26). In addition, there was a lack of association between
D543N and A318V genotypes with response to treatment (p=0.54 and p=0.31, respectively).
Interpretation & conclusion: The results indicated that genetic variations of D543N (rs17235409) might be
associated with susceptibility to CL infection. These data may be used for detection of sensitive individuals and
prevention of CL in endemic areas.
Key words A318V, cutaneous, D543N, Iran, leishmaniasis, NRAMP1
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and regulation of anti-inflammatory cytokine IL-1015–16.
It has been shown that mutations in the NRAMP1 gene re-
sult in a non-functional or unstable protein, resulting in an
increased proliferation of parasites in the macrophage17–
18. Macrophages from mice with a mutant NRAMP1 pro-
tein have deficiencies in antigen presentation, while the
presence of a NRAMP1 protein improves the function of
macrophages in susceptible mice to mycobacterium19–20.
There is a correlation between NRAMP1 muta-
tions and susceptibility to a cluster of antigenetically un-
related intracellular pathogens including HIV21, Myco-
bacterium leprae22, M. tuberculosis and Leishmania
donovani9, 23–24. Among all the known NRAMP1 poly-
morphisms, a number of variants are located in the cod-
ing regions, some of which are missense mutations while
others are silent substitutions. The missense mutations
are an aspartic acid-to-asparagine change at codon 543 in
exon 15 (D543N polymorphism) and a single-base sub-
stitution resulting in an alanine-to-valine change at codon
318 in exon 9 (A318V polymorphism). These missense
mutations are important because they may affect the func-
tion of NRAMP1 protein18, 25. Host genetic factors might
play an important role in development of the clinical mani-
festations, especially in CL26–29.
The most important hyper-endemic area of CL in Iran
is the Isfahan province, where only a certain percentage
of individuals bitten by an infected sandfly, develop CL.
Also, reinfection has been observed in some individuals
with a previous history of CL infection. These observa-
tions prompted us to investigate the impact of genetic
factors on susceptibility to CL infection and responses to
therapy in different patients. Due to the importance of
NRAMP1, especially A318V (rs201565523) and D543N
(rs17235409) polymorphisms in the control of intracel-
lular infections, the associations of the mentioned poly-
morphisms with susceptibility to CL along with the host
responses to treatment were investigated in this study.
MATERIAL & METHODS
Subjects and samples
The current study was performed in the Antimicrobial
Research Center, Iran University of Medical Sciences,
Tehran, Iran. University Ethics Committee approved the
study and informed consent was obtained for all subjects.
The samples were collected from Isfahan province, where
CL is highly endemic. In order to exclude the effect of mul-
tiple ethnic groups, all samples were obtained from the same
region (Isfahan province, Iran); also, all participants were
the original inhabitants of Isfahan province. The clinical
and demographic information were obtained through medi-
cal records. The patients were excluded if they suffered from
other significant medical conditions such as cardiac, renal,
malnutrition or liver disorders. Also pregnant and lactat-
ing women, children >5 yr of age, and patients with a posi-
tive history of systemic or local therapy for CL and any other
diseases within the last six months were excluded.
The blood samples were collected from 150 CL pa-
tients (mean age 28.94 ± 11.78) who were referred to the
Skin Disease and Leishmaniasis Research Center
(Sedigheh Tahereh Center, Isfahan, Iran) during 2012–
13. Blood samples of healthy controls (n=136) were col-
lected from blood donors (mean age 35.40 ± 9.49) in
Isfahan Blood Transfusion Service. Cutaneous leishma-
niasis was confirmed in those with clinically apparent skin
lesions based on direct smear and/or culture. Leishmania
major and L. tropica were considered as the agents of CL
in this center according to the epidemiological data. Since,
L. major species of Leishmania were identified as a ma-
jor diagnosed species, and to exclude the effect of differ-
ent species, only patients infected with L. major were re-
cruited in this study. In addition, only patients with a single
lesion were considered in order to omit the effect of le-
sions number on the outcome.
All the included patients were treated with a weekly
intralesional injection of meglumine antimoniate
(Glucantime, Paris, France) at a dose of 20 mg/kg/day
for six weeks. The patients were assessed at Weeks 0, 1,
2, 3, 4, 5 and 6 of treatment and thereafter monthly up to
six months. At every visit, direct smear and/or culture
were performed. Based on the results of the treatment,
patients were classified as complete improvement (dis-
appearance of induration in lesion with re-epithelializa-
tion and flattening), partial improvement (reduction in
lesion size and induration with no sign of any epidermal
crease in lesion), and no improvement (no clinical change
in lesions and decrease in their size). The obtained treat-
ment outcome, from the end of the follow-up time was
considered as the final report.
DNA extraction
Whole blood sample was collected in tubes contain-
ing EDTA. The genomic DNA was extracted from white
blood cells using Cinna pure DNA kit (Sinaclon Co,
Tehran, Iran) according to the manufacturers’ instructions
and stored at –80°C.
Genotyping
Genotyping for the D543N (rs17235409) and A318V
(rs201565523) polymorphisms was performed by PCR-
RFLP with two primers described in Table 1. PCR reac-
tion volume for both polymorphisms was 25 μl, including
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Table 1. Sequence of primers and characteristics of polymorphisms
Name Nucleotide and amino Primers, 5' to 3' Restriction Genotype Fragment size
acid change enzyme
A 318 V Ala (GCG) to Val (GTG) F: TCCTTGATCTTCGTAGTCTC BsoFl TT 232 bp
in exon 9 R: GGCTTACAGGACATGAGTAC CT 232, 171 and 61 bp
CC 171 and 61 bp
D 543 N Asp (GAC) to Asn (AAC) F: GCATCTCCCCAATTCATGGT Avall GG 126, 79 and 39 bp
in exon 15 R: AACTGTCCCACTCTATCCTG GA 126, 79, 39 and 205 bp
AA 205 and 39 bp
12.5 μl master mix (Sinaclon Co, Tehran, Iran), 0.15 μg of
genomic DNA and 0.4 μl (50 pmol/μl) each of the two
primers (reverse and forward). After an initial incubation
at 94 °C for 4 min, the temperature cycles (n=30) used
were 94 °C for 60 s, 58 °C for 90 s and 72 °C for 40 s with
a final extension step of 10 min at 72 °C. All PCR products
were resolved by electrophoresis in a 2.5% agarose gel
and stained with ethidium bromide. The PCR products
were digested using restriction enzymes BsoFl (for A318V)
and AvaII (for D543N) under conditions recommended
by the enzyme supplier (Thermo Scientific Co, Lithuania).
Restriction products were separated in a 12% polyacryla-
mide gel and stained with ethidium bromide. The frag-
ment patterns are presented in Table 1.
Statistical analysis
Data were analyzed using the statistical software pack-
age SPSS 18.0, Chicago. The quantitative parameters were
reported as mean ± SD. Associations of alleles and geno-
types of polymorphisms with susceptibility to CL and
treatment results were analyzed by χ2-test and Fisher’s
exact test as per requirement. In order to test the Hardy-
Weinberg equilibrium, all frequencies of various geno-
types were compared using the χ2-test. A p-value of
< 0.05 was considered to be significant with 95% confi-
dence intervals (CI).
RESULTS
Population characteristics
The characteristics of 286 subjects (150 patients and
136 controls) are summarized in Table 2. Cutaneous leish-
maniasis patients included 71 (47.3%) men and 79 (52.7%)
women with a mean age of 28.94 ± 11.78. There were no
significant differences between the two groups with re-
spect to age and sex (p=0.22 and 0.63, respectively).
D543N (rs17235409) and A318V (rs201565523) geno-
typing
Genotype and allelic frequencies of D543N
(rs17235409) and A318V (rs201565523) gene polymor-
phisms of the patients and controls are presented in
Table 3. The genotype distributions were in concordance
with Hardy-Weinberg equilibrium in each group. D543N
(rs17235409) genotypes observed in the examined pa-
tients included GG in 115 (76.6%) and GA in 35 (23.4%)
individuals, while no AA genotype was detected in con-
trol or the patients. The genotype distribution was sig-
nificantly (p=0.008) different between patient and the
control groups. In addition, G and A allele distributions
for this variant were statistically significant between pa-
tient and the control groups (p=0.01, OR: 95%, CI: 2.263/
1.207–4.243). Genotype frequencies observed for A318V
(rs201565523) were CC in 144 patients (96%) and CT in
six patients (4%) with no TT detection. The genotype dis-
tributions were not significantly different between patients
and the healthy controls (p=0.26). Also, C and T
allele distributions for this variant were not statistically
significant between the two groups (p=0.63, OR/95% CI:
2.262/0.837–6.111).
Effect of gene polymorphism on treatment results
The relative effect of the studied variations on treat-
ment result is shown in Table 4. Genotype distributions
for D543N (rs17235409) were not significantly different
(p=0.54) among patient categories, i.e. no improvement,
partial improvement and complete improvement. The re-
sults showed that in no improvement patients, GG geno-
type was present in 35 (81.39%) patients, while GA geno-
Table 2. Demographic data of the subjects
Variables CL patients Control group p-value*
(n = 150) (n = 136)
Sex
Male 71 (47.3) 60 (44.11) 0.63
Female 79 (52.7) 76 (55.89)
Age (yr) ± SD 28.94 ± 11.78 35.40 ± 9.49 0.22
Species of Leishmania
L. major 150 (100) 0 –
CL—Cutaneous leishmaniasis. Figures in parentheses indicate
percentages; *p-value ≤ 0.05 means statistically significant.
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type was present in only 8 (18.61%) patients. Genotype
distributions in partial improvement patients were— GG
in 53 (76.81%) patients and GA in 16 (23.19%) patients.
AA genotype was not found in any of the subgroups. Also,
the genotype distributions for the A318V (rs201565523)
among the patient categories were not significant (p=0.31).
Among no improvement patients, the CC genotype was
found in 40 (93.02%) and CT in 3 (6.98%) individuals.
The CC and CT genotypes were identified in 68 (98.5%)
and 1 (1.5%) of partial improvement patients, respectively.
TT genotype was not found in any of the subgroups.
DISCUSSION
The protein encoded by NRAMP1 gene, which is ex-
pressed in the macrophage, acts by transferring divalent
metal ions across the phagosomal membrane and might
be a critical factor for resistance to some microorganisms.
Several polymorphisms of NRAMP1 gene have been
evaluated in clinical studies21–24. The majority of previ-
ous investigations have focused on the association
between NRAMP1 gene and diseases such as lung
tuberculosis19, 30, Crohn’s disease31, rheumatoid
arthritis32, chronic periodontitis33, leprosy34, visceral
leishmaniasis35–37, and CL37–38. However, to our knowl-
edge, there are no published reports on the association
between NRAMP1 gene polymorphisms with response to
treatment in the Iranian CL patients. Thus, the present
study focused on the effects of D543N (rs17235409) and
Table 3. Frequency of alleles and genotypes of NRAMP1 polymorphisms (A318V and D543N) in
cutaneous leishmaniasis (CL) patient and the control groups
Variables CL patients Control p-value* OR (95% CI)
(n = 150) (n = 136)
A318V
Genotype (%)
CC 144 (96) 125 (91.9) 0.26
CT 6 (4) 10 (7.35)
TT 0 1 (0.75)
(TT+CT=1 and CC=2)
TT + CT 6 (4) 11 (8.1) 0.21 2.112 (0.759–5.876)
CC 144 (96) 125 (91.9)
Allele (%)
C 294 (98) 260 (95.5) 0.63 2.262 (0.0.837–6.111)
T 6 (2) 12 (4.5)
D543N
Genotype (%)
GG 115 (76.6) 121 (88.9) 0.008
GA 35 (23.4) 15 (11.1)
AA 0 0
(AA+GA=1 and GG=2)
AA+GA 35 (23.4) 15 (11.1) 0.008 2.455 (1.273–4.734)
GG 115 (76.6) 121 (88.9)
Allele (%)
A 35 (11.6) 15 (5.51) 0.01 2.263 (1.207–4.243)
G 265 (88.4) 257 (94.49)
*p-value ≤0.05 means statistically significant.
Table 4. Distribution of D543N (rs17235409) and A318V
(rs201565523) genotypes in complete improvement, partial
improvement and no improvement patients
Variables Complete Partial No p-value
improvement improvement improvement
(n = 38) (n = 69) (n = 43)
A318V
Genotype (%)
CC 36 (94.7) 68 (98.5) 40 (93.02) 0.31
CT 2 (5.3) 1 (1.5) 3 (6.98)
TT 0 0 0
Allele (%)
T 2 (2.6) 1 (0.72) 3 (3.48) 0.31
C 74 (97.4) 137 (99.28) 83 (96.52)
D543N
Genotype (%)
GG 27 (71.05) 53 (76.81) 35 (81.39) 0.54
GA 11 (28.95) 16 (23.19) 8 (18.61)
AA 0 0 0
Allele (%)
G 65 (85.5) 122 (88.40) 78 (90.7) 0.59
A 11 (14.5) 16 (11.6) 8 (9.3)
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A318V (rs201565523) polymorphisms on susceptibility
to CL and the status of treatment outcome among suscep-
tible individuals. The results revealed that the D543N
(rs17235409) allele and genotype frequencies between
patients and controls were statistically significant
(p=0.008). The GA genotype was detected in 23.4% of
the patients and in 11.1% of the controls. Moreover, fre-
quency of allele A was more in patients than the controls
(11.6 vs 5.51%). Although, Samaranayake et al38, had
reported a lack of association between the GA genotype
and CL infection, however, the results of this study indi-
cated that the GA genotype indeed favours susceptibility
to CL. Such conflicting results have also been reported
on the association between D543N polymorphism and
certain other diseases. A number of studies have
indicated significant differences in D543N allele
and genotype distributions between patients and
controls33, 36, 39–42–43, however, there are some
exceptions30, 34–35, 37. Indeed, D543N polymorphism by
substituting the Asp (as negatively charged amino acid)
with Asn (an uncharged residue) in the cytoplasmic
carboxy-terminal domain could affect protein function and
possibly alter the macrophage function. Therefore, its ef-
fect on susceptibility to CL is not unexpected.
As far as A318V (rs201565523) polymorphism is
considered, no significant difference was detected in al-
lele and genotype frequencies between the patients and
controls. This finding is in agreement with the results of
other studies32, 37–38. A318V polymorphism exchanges the
Ala amino acid (with a small and hydrophobic R group)
with a Val residue (a medium size and hydrophobic
R group) in the extracellular region of the NRAMP1. The
R groups in both amino acids are non-polar aliphatic with
nearly similar chemical and physical properties. Thus, this
finding along with previous reports support our hypoth-
esis that Ala to Val substitution may not affect protein
function.
The data on the response to treatment showed that
D543N and A318V variants are not associated with
patient’s response towards the treatment provided. So,
the presence of the Asn and Val residues at positions 543
and 318, respectively, of the NRAMP1 protein is not as-
sociated with resistance to treatment. Whereas, previous
studies on cancer patients had reported a potential effect
of NRAMP1 on responses to BCG immunotherapy in pa-
tients with bladder cancer, wherein the patients at high
risk of recurrence were those carrying the GA genotype42.
However, Yang et al32 in Korea reported that treated and
untreated patients with rheumatoid arthritis had identical
genotypes for NRAMP1 polymorphisms. Also, Mehrotra
et al35, showed that treatment in VL patients with three
genotypes of 5' (GT)n polymorphisms had no effect on
NRAMP1 gene expression. Similarly in another study, no
significant difference was observed between NRAMP1
gene polymorphisms and recurrence time, muscle inva-
sion frequency or disease-free survival in patients with
non-muscle-invasive bladder cancer; nevertheless, a
shorter time to tumor recurrence was observed in group
with GG genotype of D543N polymorphisms44. There-
fore, it is apparent that more studies with an emphasis on
treatment type are required to determine the effect of
NRAMP1 polymorphisms on the outcome of treatments.
CONCLUSION
In conclusion, the results from this study showed that
the inheritance of some genotypes is associated with poly-
morphisms of NRAMP1 gene, such as the D543N and
A318V, which appear to influence the function of
NRAMP1 protein, and thus may be indicative of an asso-
ciation between host genetic factors and susceptibility to
CL. However, in order to approve the role of NRAMP1
polymorphisms in susceptibility to CL infection, more
studies are needed to investigate the effects of gene poly-
morphisms on the expression and function of the protein.
Further analysis is also required to reveal the mechanisms
that may influence the progression of CL. These data will
increase our knowledge on macrophage involving disor-
ders such as autoimmune diseases and intracellular in-
fections. The results of the current study might be useful
in the control of CL infection in high risk individuals liv-
ing in the endemic region of Isfahan.
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